Logo
x

Search

Subscribe Now

Treatment-Naïve

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chroni...

  • March 9, 2020
AbbVie's Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients with Chronic Hepatitis C and Compensated Cirrhosis

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients with Chronic Hepati...

  • August 2, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.